[go: up one dir, main page]

DK1663298T3 - Anvendelse af prolinspecifikke endoproteaser til hydrolyse af peptider og proteiner - Google Patents

Anvendelse af prolinspecifikke endoproteaser til hydrolyse af peptider og proteiner Download PDF

Info

Publication number
DK1663298T3
DK1663298T3 DK04765616.0T DK04765616T DK1663298T3 DK 1663298 T3 DK1663298 T3 DK 1663298T3 DK 04765616 T DK04765616 T DK 04765616T DK 1663298 T3 DK1663298 T3 DK 1663298T3
Authority
DK
Denmark
Prior art keywords
endoproteas
hydrolyse
proline
peptides
proteins
Prior art date
Application number
DK04765616.0T
Other languages
English (en)
Inventor
Melissa Harvey
Luppo Edens
Der Hoeven Robertus Antonius Mijndert Van
Roos Andre Leonardus De
Original Assignee
Dsm Ip Assets Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dsm Ip Assets Bv filed Critical Dsm Ip Assets Bv
Application granted granted Critical
Publication of DK1663298T3 publication Critical patent/DK1663298T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
    • A23J3/00—Working-up of proteins for foodstuffs
    • A23J3/30—Working-up of proteins for foodstuffs by hydrolysis
    • A23J3/32—Working-up of proteins for foodstuffs by hydrolysis using chemical agents
    • A23J3/34—Working-up of proteins for foodstuffs by hydrolysis using chemical agents using enzymes
    • A23J3/346—Working-up of proteins for foodstuffs by hydrolysis using chemical agents using enzymes of vegetable proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Nutrition Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
DK04765616.0T 2003-09-23 2004-09-23 Anvendelse af prolinspecifikke endoproteaser til hydrolyse af peptider og proteiner DK1663298T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03078012 2003-09-23
EP03078496 2003-11-06
PCT/EP2004/010782 WO2005027953A2 (en) 2003-09-23 2004-09-23 Use of proline specific endoproteases to hydrolyse peptides and proteins

Publications (1)

Publication Number Publication Date
DK1663298T3 true DK1663298T3 (da) 2019-10-14

Family

ID=34379381

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04765616.0T DK1663298T3 (da) 2003-09-23 2004-09-23 Anvendelse af prolinspecifikke endoproteaser til hydrolyse af peptider og proteiner

Country Status (8)

Country Link
US (3) US8524225B2 (da)
EP (1) EP1663298B1 (da)
JP (2) JP5328100B2 (da)
DK (1) DK1663298T3 (da)
ES (1) ES2746173T3 (da)
HU (1) HUE044812T2 (da)
RU (1) RU2370279C2 (da)
WO (1) WO2005027953A2 (da)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6632429B1 (en) 1999-12-17 2003-10-14 Joan M. Fallon Methods for treating pervasive development disorders
US20070053895A1 (en) * 2000-08-14 2007-03-08 Fallon Joan M Method of treating and diagnosing parkinsons disease and related dysautonomic disorders
US8030002B2 (en) 2000-11-16 2011-10-04 Curemark Llc Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions
BR0210680A (pt) 2001-07-18 2004-09-21 Dsm Ip Assets Bv Processo para a hidrólise de proteìnas do leite
EP1612558A1 (en) * 2004-06-30 2006-01-04 Academisch Ziekenhuis Leiden Method for detecting gluten
US20060198838A1 (en) * 2004-09-28 2006-09-07 Fallon Joan M Combination enzyme for cystic fibrosis
WO2006097949A1 (en) * 2005-03-16 2006-09-21 Actial Farmacêutica, Lda. Mixture of at least 6 species of lactic acid bacteria and/or bifidobacteria in the manufacture of sourdough
US20080058282A1 (en) 2005-08-30 2008-03-06 Fallon Joan M Use of lactulose in the treatment of autism
US20070116695A1 (en) * 2005-09-21 2007-05-24 Fallon Joan M Pharmaceutical preparations for attention deficit disorder, attention deficit hyperactivity disorder and other associated disorders
WO2007088062A2 (en) * 2006-02-02 2007-08-09 Dsm Ip Assets B.V. Food product comprising a proline specific protease
JP5256562B2 (ja) * 2006-07-13 2013-08-07 ディーエスエム アイピー アセッツ ビー．ブイ． 改良醸造方法
US20080169333A1 (en) 2007-01-11 2008-07-17 Shelton Frederick E Surgical stapler end effector with tapered distal end
CA2680590C (en) * 2007-03-16 2017-10-17 Jonathan David Gass Combination enzyme therapy for digestion of dietary gluten
CA2696250C (en) * 2007-08-13 2016-12-06 Commonwealth Scientific And Industrial Research Organisation Barley with low levels of hordeins
RU2010114061A (ru) * 2007-09-11 2011-10-20 Мондобайотек Лабораториз Аг (Li) ПРИМЕНЕНИЕ ПЕПТИДА His-Ser-Leu-Gly-Lys-Trp-Leu-His-Pro-Asp-Lys-Phe ИНДИВИДУАЛЬНО ИЛИ В КОМБИНАЦИИ С ПЕПТИДОМ Gly-Arg-Gly-Asp-Asn-Pro-OH В КАЧЕСТВЕ ТЕРАПЕВТИЧЕСКОГО СРЕДСТВА
US20100322912A1 (en) * 2007-12-10 2010-12-23 Chaitan Khosla Combination Enzyme Therapy for Gastric Digestion of Dietary Gluten in Celiac Sprue Patients
US8658163B2 (en) 2008-03-13 2014-02-25 Curemark Llc Compositions and use thereof for treating symptoms of preeclampsia
US8084025B2 (en) 2008-04-18 2011-12-27 Curemark Llc Method for the treatment of the symptoms of drug and alcohol addiction
TW201000634A (en) * 2008-05-30 2010-01-01 Dsm Ip Assets Bv Proline-specific protease
US20090324730A1 (en) * 2008-06-26 2009-12-31 Fallon Joan M Methods and compositions for the treatment of symptoms of complex regional pain syndrome
US9320780B2 (en) * 2008-06-26 2016-04-26 Curemark Llc Methods and compositions for the treatment of symptoms of Williams Syndrome
US11016104B2 (en) * 2008-07-01 2021-05-25 Curemark, Llc Methods and compositions for the treatment of symptoms of neurological and mental health disorders
US10776453B2 (en) * 2008-08-04 2020-09-15 Galenagen, Llc Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain
US20100092447A1 (en) 2008-10-03 2010-04-15 Fallon Joan M Methods and compositions for the treatment of symptoms of prion diseases
CN102300989B (zh) 2009-01-06 2015-12-09 柯尔朗恩有限责任公司 用于治疗或预防金黄色葡萄球菌感染以及用于根除或减少表面上金黄色葡萄球菌的组合物和方法
EP2373693A4 (en) 2009-01-06 2012-04-25 Curelon Llc COMPOSITIONS AND METHODS FOR THE TREATMENT OR PREVENTION OF ORAL INFECTIONS BY E. COLI
US9056050B2 (en) 2009-04-13 2015-06-16 Curemark Llc Enzyme delivery systems and methods of preparation and use
WO2011000773A1 (en) 2009-07-02 2011-01-06 Dsm Ip Assets B.V. Testing efficacy for celiac disease
US9511125B2 (en) 2009-10-21 2016-12-06 Curemark Llc Methods and compositions for the treatment of influenza
EP2531521B1 (en) 2010-02-02 2017-09-06 Amano Enzyme USA., Ltd. Use of proteases for gluten intolerance
US20120244362A1 (en) 2011-03-22 2012-09-27 Pramanik Pranabes K Multi-layer sheet structure
WO2012145651A2 (en) 2011-04-21 2012-10-26 Curemark, Llc Compounds for the treatment of neuropsychiatric disorders
US20140205587A1 (en) * 2011-06-17 2014-07-24 Alvine Pharmaceuticals, Inc. Proteases for Degrading Gluten
JPWO2013047082A1 (ja) * 2011-09-29 2015-03-26 天野エンザイム株式会社 外因性オピオイドペプチド分解酵素剤
ES2595500T3 (es) 2011-12-06 2016-12-30 Fondazione Istituto Insubrico Di Ricerca Per La Vita Nuevas proteasas que pueden hidrolizar péptidos y proteínas de gluten a un pH ácido, procedentes del actinomiceto Actinoallomurus
US10350278B2 (en) 2012-05-30 2019-07-16 Curemark, Llc Methods of treating Celiac disease
US20130344042A1 (en) * 2012-06-20 2013-12-26 Gretchen Tanbonliong Dietary management of celiac disease and food allergy
BR102013003182B1 (pt) * 2013-02-08 2019-03-19 Vitor Carlos Veit Processo de fabricação de cerveja sem glúten
US9345741B2 (en) 2013-03-15 2016-05-24 Mead Johnson Nutrition Company Nutritional composition containing a peptide component with adiponectin simulating properties and uses thereof
US9352020B2 (en) 2013-03-15 2016-05-31 Mead Johnson Nutrition Company Reducing proinflammatory response
US9345727B2 (en) * 2013-03-15 2016-05-24 Mead Johnson Nutrition Company Nutritional compositions containing a peptide component and uses thereof
US8889633B2 (en) 2013-03-15 2014-11-18 Mead Johnson Nutrition Company Nutritional compositions containing a peptide component with anti-inflammatory properties and uses thereof
US9289461B2 (en) 2013-03-15 2016-03-22 Mead Johnson Nutrition Company Reducing the risk of autoimmune disease
US9138455B2 (en) 2013-03-15 2015-09-22 Mead Johnson Nutrition Company Activating adiponectin by casein hydrolysate
BR112015029755A2 (pt) * 2013-05-31 2017-07-25 Dsm Ip Assets Bv endoprotease prolina-específica imobilizada
EP3008161A4 (en) 2013-06-13 2017-02-22 Commonwealth Scientific and Industrial Research Organisation Barley with very low levels of hordeins
CA3214545A1 (en) * 2013-07-12 2015-01-15 The A2 Milk Company Limited Beta-casein a2 and reducing or preventing symptoms of lactose intolerance
EP2883458A1 (en) 2013-12-11 2015-06-17 DSM IP Assets B.V. Medicament and method for treating innate immune response diseases
EP3146043B1 (en) 2014-05-19 2019-06-26 DSM IP Assets B.V. Proline-specific endoprotease
WO2015177153A1 (en) 2014-05-19 2015-11-26 Dsm Ip Assets B.V. Proline-specific endoprotease
WO2015177152A1 (en) 2014-05-19 2015-11-26 Dsm Ip Assets B.V. Proline-specific endoprotease
JP6244601B2 (ja) * 2014-07-01 2017-12-13 ディーエスエム アイピー アセッツ ビー．ブイ． 低グルテン酵母加水分解産物
JP6739767B2 (ja) * 2015-03-04 2020-08-12 学校法人日本大学 タンパク質シート及びタンパク質シートの製造方法
FR3035664B1 (fr) * 2015-04-29 2020-02-21 Malteries Soufflet Utilisation de cysteine endoprotease pour diminuer le trouble de boissons
JP6616198B2 (ja) * 2016-01-21 2019-12-04 オリエンタル酵母工業株式会社 パン類の品質改良剤及びパン類の製造方法
WO2018191233A1 (en) 2017-04-10 2018-10-18 Curemark, Llc Compositions for treating addiction
CN107814836A (zh) * 2017-12-01 2018-03-20 浙江熊猫乳业集团股份有限公司 一种生物活性多肽fpgpipns及其制备方法和应用
EP3830258A1 (en) * 2018-07-31 2021-06-09 DuPont Nutrition Biosciences ApS Proline specific endopeptidases
AU2019370035B2 (en) * 2018-10-29 2024-09-05 The A2 Milk Company Limited Beta-casein analysis of milk and milk products
CA3172390A1 (en) * 2020-02-19 2021-08-26 Perfect Day, Inc. Hypoallergenic recombinant milk proteins and compositions comprising the same
US11541009B2 (en) 2020-09-10 2023-01-03 Curemark, Llc Methods of prophylaxis of coronavirus infection and treatment of coronaviruses
JP2022135015A (ja) * 2021-03-04 2022-09-15 国立大学法人東京工業大学 オピオイド受容体作動剤
EP4437856A1 (en) 2023-03-31 2024-10-02 DSM IP Assets B.V. Novel enzyme composition and novel beer brewing process
WO2024200535A1 (en) 2023-03-27 2024-10-03 Dsm Ip Assets B.V. Endoprotease composition
WO2025012442A1 (en) * 2023-07-13 2025-01-16 Dsm Ip Assets B.V. Rapeseed protein hydrolysate

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2451388A1 (de) 1973-10-31 1975-05-07 James Joseph Phelan Verfahren zur entgiftung von kleber in nahrungsmitteln
DD262999A1 (de) 1987-07-27 1988-12-21 Adw Ddr Verfahren zur herstellung eines diaetetikums fuer zoeliakie- und spruekranke
ES2197143T3 (es) 1991-07-24 2004-01-01 Novartis Ag Adn que codifica para prolilendopeptidasa.
US6251391B1 (en) 1999-10-01 2001-06-26 Klaire Laboratories, Inc. Compositions containing dipepitidyl peptidase IV and tyrosinase or phenylalaninase for reducing opioid-related symptons
AU1142001A (en) 2000-10-19 2002-04-29 Dsm N.V. Protein hydrolysates
WO2002046381A2 (en) * 2000-12-07 2002-06-13 Dsm N.V. Method for the prevention or reduction of haze in beverages
ATE386110T1 (de) 2000-12-07 2008-03-15 Dsm Ip Assets Bv Prolylendoprotease aus aspergillus niger
DK1224869T3 (da) 2001-01-12 2004-12-13 Campina Bv Fremgangsmåde til fremstilling af et glutenfrit peptidpræparat samt det således opnåede præparat
WO2002068623A2 (en) 2001-02-23 2002-09-06 Dsm Ip Assets B.V. Genes encoding proteolytic enzymes from aspargilli
BR0210680A (pt) 2001-07-18 2004-09-21 Dsm Ip Assets Bv Processo para a hidrólise de proteìnas do leite
NO318426B1 (no) 2001-10-02 2005-04-18 Neurozym Biotech As Et materiale for a senke konsentrasjonen av patogene tarmpeptider
ES2361993T5 (es) * 2002-02-14 2014-12-09 The Board Of Trustees Of The Leland Stanford Junior University Tratamiento con enzimas de productos alimenticios para celiaquía
US8143210B2 (en) * 2002-02-14 2012-03-27 The Board Of Trustees Of The Leland Stanford Junior University Enzyme treatment of foodstuffs for celiac sprue
EP1509609B1 (en) * 2002-06-04 2015-04-22 DSM IP Assets B.V. Protein hydrolysate rich in tripeptides
JP4713150B2 (ja) 2002-06-07 2011-06-29 ディーエスエム アイピー アセッツ ビー．ブイ． 飲料中の濁り防止又は低減の改良方法
EP1534314B1 (en) 2002-09-04 2014-10-22 DSM IP Assets B.V. A nutritional and therapeutic composition of an insulin sensitizer and a peptide fraction
JP2008505653A (ja) 2004-07-12 2008-02-28 ディーエスエム アイピー アセッツ ビー．ブイ． 血圧降下タンパク質加水分解物
US7879804B2 (en) 2004-12-22 2011-02-01 Dsm Ip Assets B.V. Blood pressure lowering peptides in a single enzymatic step
US20140205587A1 (en) * 2011-06-17 2014-07-24 Alvine Pharmaceuticals, Inc. Proteases for Degrading Gluten

Also Published As

Publication number Publication date
US20140206036A1 (en) 2014-07-24
ES2746173T3 (es) 2020-03-05
RU2370279C2 (ru) 2009-10-20
US20070031399A1 (en) 2007-02-08
JP2011120601A (ja) 2011-06-23
RU2006113586A (ru) 2006-08-10
WO2005027953A2 (en) 2005-03-31
US20110142987A1 (en) 2011-06-16
WO2005027953A3 (en) 2005-06-16
US8524225B2 (en) 2013-09-03
HUE044812T2 (hu) 2019-11-28
JP2007505639A (ja) 2007-03-15
JP5328100B2 (ja) 2013-10-30
EP1663298B1 (en) 2019-07-17
EP1663298A2 (en) 2006-06-07

Similar Documents

Publication Publication Date Title
DK1663298T3 (da) Anvendelse af prolinspecifikke endoproteaser til hydrolyse af peptider og proteiner
DK1680443T3 (da) Stabiliserede alfa-helix-peptider og anvendelser heraf
DK1667986T3 (da) Acetonesolvat af dimethoxydocetaxel og fremgangsmåde til fremstilling heraf
DK2508521T4 (da) Dimaleat af en aminocrotonylforbindelse og fremgangsmåde til fremstilling deraf
DK1656370T3 (da) Heterocykliske biarylforbindelser og fremgangsmåder til fremstilling og anvendelse af samme
DK3144240T3 (da) Stabelbar pakning og fremgangsmåde til tilvejebringelse heraf
DK1578771T3 (da) Remodellering og glycokonjugering af peptider
EP1732581A4 (en) POLYPEPTIDE TRANSDUCTION AND FUSOGENIC PEPTIDES
DK4104859T3 (da) Fremgangsmåde til opkoncentrering af antistoffer og terapeutiske produkter deraf
DK1620551T3 (da) Phospholipase og fremgangsmåde til fremstilling deraf
IS7966A (is) Pyrazól og aðferðir við að búa þau til og notkun þeirra
DK1587821T6 (da) Sammensætninger og fremgangsmåder til stabilisering af trans-thyretin og inhibering af transthyretin-fejlfoldning
DK1440908T3 (da) Indsats og fremgangsmåde til fremstilling af drikkevarer
ATE480567T1 (de) Hochkonzentrierter antikörper und proteinformulierungen
DK1677735T3 (da) Fremgangsmåder og sammensætninger til modulering af adipocytfunktion
EP1909831A4 (en) SELF-BUFFING PROTEIN FORMULATIONS
IS7475A (is) Þrí-staðgengnir heteróarýlhópar og aðferðir til að smíða og nota slík efni
NO20033387L (no) Modifiserte antistoffer og fremgangsmåter for anvendelse
DK1638999T3 (da) Sammensætninger og fremgangsmåder til øgning af knoglemineralisering
DK1509990T3 (da) Konfiguration og fremgangsmåde til beskyttelse af omformerorganer
DK1291356T3 (da) Fremgangsmåde til hurtig oplösningssyntese af peptider
DE602005012555D1 (de) Künstliches protein zur absoluten quantifizierung von proteinen und verwendungen davon
DK1737971T3 (da) Blandinger af bindingsproteiner
NO20035562L (no) System og fremgangsmate for forenklet initiering av konferanser
DK1523243T3 (da) Mælkeproteinisolat og metode til fremstilling af samme